Top

Journal of Ovarian Research

Published in:

Open Access 01-12-2012 | Research

Discovery of dachshund 2 protein as a novel biomarker of poor prognosis in epithelial ovarian cancer

Authors: Björn Nodin, Marie Fridberg, Mathias Uhlén, Karin Jirström

Published in: Journal of Ovarian Research | Issue 1/2012

Abstract

Background

The Dachshund homolog 2 (DACH2) gene has been implicated in development of the female genital tract in mouse models and premature ovarian failure syndrome, but to date, its expression in human normal and cancerous tissue remains unexplored. Using the Human Protein Atlas as a tool for cancer biomarker discovery, DACH2 protein was found to be differentially expressed in epithelial ovarian cancer (EOC). Here, the expression and prognostic significance of DACH2 was further evaluated in ovarian cancer cell lines and human EOC samples.

Methods

Immunohistochemical expression of DACH2 was examined in tissue microarrays with 143 incident EOC cases from two prospective, population-based cohorts, including a subset of benign-appearing fallopian tubes (n = 32). A nuclear score (NS), i.e. multiplier of staining fraction and intensity, was calculated. For survival analyses, cases were dichotomized into low (NS < = 3) and high (NS > 3) using classification and regression tree analysis. Kaplan Meier analysis and Cox proportional hazards modelling were used to assess the impact of DACH2 expression on survival. DACH2 expression was analysed in the cisplatin sensitive ovarian cancer cell line A2780 and its cisplatin resistant derivative A2780-Cp70. The specificity of the DACH2 antibody was tested using siRNA-mediated silencing of DACH2 in A2780-Cp70 cells.

Results

DACH2 expression was considerably higher in the cisplatin resistant A2780-Cp70 cells compared to the cisplatin-sensitive A2780 cells. While present in all sampled fallopian tubes, DACH2 expression ranged from negative to strong in EOC. In EOC, DACH2 expression correlated with several proteins involved in DNA integrity and repair, and proliferation. DACH2 expression was significantly higher in carcinoma of the serous subtype compared to non-serous carcinoma. In the full cohort, high DACH2 expression was significantly associated with poor prognosis in univariable analysis, and in carcinoma of the serous subtype, DACH2 remained an independent factor of poor prognosis.

Conclusions

This study provides a first demonstration of DACH2 protein being expressed in human fallopian tubes and EOC, with the highest expression in serous carcinoma where DACH2 was found to be an independent biomarker of poor prognosis. Future research should expand on the role of DACH2 in ovarian carcinogenesis and chemotherapy resistance.

Available only for authorised users

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009,59(4):225–249. 10.3322/caac.20006PubMedCrossRef

Hennessy BT, Coleman RL, Markman M: Ovarian cancer. Lancet 2009,374(9698):1371–1382. 10.1016/S0140-6736(09)61338-6PubMedCrossRef

Ponten F, Jirstrom K, Uhlen M: The Human Protein Atlas--a tool for pathology. J Pathol 2008,216(4):387–393. 10.1002/path.2440PubMedCrossRef

Bjorling E, Lindskog C, Oksvold P, Linne J, Kampf C, Hober S, Uhlen M, Ponten F: A web-based tool for in silico biomarker discovery based on tissue-specific protein profiles in normal and cancer tissues. Mol Cell Proteomics 2008,7(5):825–844. 10.1074/mcp.M700411-MCP200PubMedCrossRef

Keisman EL, Baker BS: The Drosophila sex determination hierarchy modulates wingless and decapentaplegic signaling to deploy dachshund sex-specifically in the genital imaginal disc. Development 2001,128(9):1643–1656.PubMed

Mardon G, Solomon NM, Rubin GM: Dachshund encodes a nuclear protein required for normal eye and leg development in Drosophila. Development 1994,120(12):3473–3486.PubMed

Davis RJ, Shen W, Heanue TA, Mardon G: Mouse Dach, a homologue of Drosophila dachshund, is expressed in the developing retina, brain and limbs. Development genes and evolution 1999,209(9):526–536. 10.1007/s004270050285PubMedCrossRef

Kozmik Z, Pfeffer P, Kralova J, Paces J, Paces V, Kalousova A, Cvekl A: Molecular cloning and expression of the human and mouse homologues of the Drosophila dachshund gene. Development genes and evolution 1999,209(9):537–545. 10.1007/s004270050286PubMedCrossRef

Heanue TA, Davis RJ, Rowitch DH, Kispert A, McMahon AP, Mardon G, Tabin CJ: Dach1, a vertebrate homologue of Drosophila dachshund, is expressed in the developing eye and ear of both chick and mouse and is regulated independently of Pax and Eya genes. Mechanisms of development 2002,111(1–2):75–87. 10.1016/S0925-4773(01)00611-6PubMedCrossRef

10.

Davis RJ, Shen W, Sandler YI, Heanue TA, Mardon G: Characterization of mouse Dach2, a homologue of Drosophila dachshund. Mechanisms of development 2001,102(1–2):169–179. 10.1016/S0925-4773(01)00307-0PubMedCrossRef

11.

Davis RJ, Harding M, Moayedi Y, Mardon G: Mouse Dach1 and Dach2 are redundantly required for Mullerian duct development. Genesis 2008,46(4):205–213. 10.1002/dvg.20385PubMedCrossRef

12.

Prueitt RL, Chen H, Barnes RI, Zinn AR: Most X;autosome translocations associated with premature ovarian failure do not interrupt X-linked genes. Cytogenet Genome Res 2002,97(1–2):32–38. 10.1159/000064052PubMedCrossRef

13.

Bione S, Rizzolio F, Sala C, Ricotti R, Goegan M, Manzini MC, Battaglia R, Marozzi A, Vegetti W, Dalpra L, et al.: Mutation analysis of two candidate genes for premature ovarian failure, DACH2 and POF1B. Hum Reprod 2004,19(12):2759–2766. 10.1093/humrep/deh502PubMedCrossRef

14.

Popov VM, Zhou J, Shirley LA, Quong J, Yeow WS, Wright JA, Wu K, Rui H, Vadlamudi RK, Jiang J, et al.: The cell fate determination factor DACH1 is expressed in estrogen receptor-alpha-positive breast cancer and represses estrogen receptor-alpha signaling. Cancer Res 2009,69(14):5752–5760. 10.1158/0008-5472.CAN-08-3992PubMedCentralPubMedCrossRef

15.

Wu K, Katiyar S, Witkiewicz A, Li A, McCue P, Song LN, Tian L, Jin M, Pestell RG: The cell fate determination factor dachshund inhibits androgen receptor signaling and prostate cancer cellular growth. Cancer Res 2009,69(8):3347–3355. 10.1158/0008-5472.CAN-08-3821PubMedCentralPubMedCrossRef

16.

Nan F, Lu Q, Zhou J, Cheng L, Popov VM, Wei S, Kong B, Pestell RG, Lisanti MP, Jiang J, et al.: Altered expression of DACH1 and cyclin D1 in endometrial cancer. Cancer Biol Ther 2009,8(16):1534–1539. 10.4161/cbt.8.16.8963PubMedCrossRef

17.

Yamada Y, Arao T, Gotoda T, Taniguchi H, Oda I, Shirao K, Shimada Y, Hamaguchi T, Kato K, Hamano T, et al.: Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples. Cancer Sci 2008,99(11):2193–2199. 10.1111/j.1349-7006.2008.00935.xPubMedCrossRef

18.

Sunde JS, Donninger H, Wu K, Johnson ME, Pestell RG, Rose GS, Mok SC, Brady J, Bonome T, Birrer MJ: Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer. Cancer Res 2006,66(17):8404–8412. 10.1158/0008-5472.CAN-06-0683PubMedCrossRef

19.

Wu K, Li A, Rao M, Liu M, Dailey V, Yang Y, Di Vizio D, Wang C, Lisanti MP, Sauter G, et al.: DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumour growth. Mol Cell Biol 2006,26(19):7116–7129. 10.1128/MCB.00268-06PubMedCentralPubMedCrossRef

20.

Berglund G, Elmstahl S, Janzon L, Larsson SA: The Malmo Diet and Cancer Study. Design and feasibility. J Intern Med 1993,233(1):45–51. 10.1111/j.1365-2796.1993.tb00647.xPubMedCrossRef

21.

Berglund G, Eriksson KF, Israelsson B, Kjellstrom T, Lindgarde F, Mattiasson I, Nilsson JA, Stavenow L: Cardiovascular risk groups and mortality in an urban swedish male population: the Malmo Preventive Project. J Intern Med 1996,239(6):489–497. 10.1046/j.1365-2796.1996.483819000.xPubMedCrossRef

22.

Nodin B, Zendehrokh N, Brandstedt J, Nilsson E, Manjer J, Brennan DJ, Jirstrom K: Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival. J Ovarian Res 3: 14.

23.

Ehlen A, Brennan DJ, Nodin B, O'Connor DP, Eberhard J, Alvarado-Kristensson M, Jeffrey IB, Manjer J, Brandstedt J, Uhlen M, et al.: Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. J Transl Med 8: 78.

24.

Ehlen A, Nodin B, Rexhepaj E, Brandstedt J, Uhlen M, Alvarado-Kristensson M, Ponten F, Brennan DJ, Jirstrom K: RBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer. Translational oncology 2011,4(4):212–221.PubMedCentralPubMedCrossRef

25.

Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumour specimens. Nat Med 1998,4(7):844–847. 10.1038/nm0798-844PubMedCrossRef

26.

Kastan MB, Bartek J: Cell-cycle checkpoints and cancer. Nature 2004,432(7015):316–323. 10.1038/nature03097PubMedCrossRef

27.

Bailis JM, Forsburg SL: MCM proteins: DNA damage, mutagenesis and repair. Current opinion in genetics & development 2004,14(1):17–21. 10.1016/j.gde.2003.11.002CrossRef

28.

Dubeau L: The cell of origin of ovarian epithelial tumours. Lancet Oncol 2008,9(12):1191–1197. 10.1016/S1470-2045(08)70308-5PubMedCentralPubMedCrossRef

29.

Carlson JW, Miron A, Jarboe EA, Parast MM, Hirsch MS, Lee Y, Muto MG, Kindelberger D, Crum CP: Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol 2008,26(25):4160–4165. 10.1200/JCO.2008.16.4814PubMedCentralPubMedCrossRef

30.

Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW, et al.: A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007,211(1):26–35. 10.1002/path.2091PubMedCrossRef

Title: Discovery of dachshund 2 protein as a novel biomarker of poor prognosis in epithelial ovarian cancer
Authors: Björn Nodin
Marie Fridberg
Mathias Uhlén
Karin Jirström
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Journal of Ovarian Research / Issue 1/2012
Electronic ISSN: 1757-2215
DOI: https://doi.org/10.1186/1757-2215-5-6

At a glance: The STEP trials

Springer Medicine

Discovery of dachshund 2 protein as a novel biomarker of poor prognosis in epithelial ovarian cancer

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Current status and implications of microRNAs in ovarian cancer diagnosis and therapy

Involvement of autophagy in ovarian cancer: a working hypothesis

Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel

GPR30 regulates the EGFR-Akt cascade and predicts lower survival in patients with ovarian cancer

Suppression of cancer stemness p21-regulating mRNA and microRNA signatures in recurrent ovarian cancer patient samples

Attributes of Oct4 in stem cell biology: perspectives on cancer stem cells of the ovary